Preparation and characterization of doxorubicin loaded Fe3O4-PEG nanoparticles on AGS and MCF-7 cancer cells

Jahazi, Sheyda; Yaghoubi, Hashem; Akbari, Hossein

Preparation and characterization of doxorubicin loaded Fe3O4-PEG nanoparticles on AGS and MCF-7 cancer cells

Document Type : Original Research

Authors

Sheyda Jahazi ¹

hashem yaghoubi ²

Hossein Akbari ³

¹ M.Sc., Department of Biology, Ardabil Branch, Islamic Azad University, Ardabil, Iran

² Assistant Professor, Department of Biology, Ardabil Branch, Islamic Azad University, Ardabil, Iran

³ Assistant professor of Physics, Department of Physics, Ardabil Branch, Islamic Azad University, Ardabil, Iran.

Abstract

Iron oxide nanoparticles are one of the nano carriers that are suitable for novel drug delivery systems due to low toxicity, biocompatibility, loading capacity and controlled drug delivery to cancer cells. The purpose of this study is the synthesis of coated iron oxide nanoparticles for delivery of Doxorubicin (DOX) and its effects on cancer cells.

In this study, Fe₃O₄ magnetic nanoparticles were synthesized by Polyol method, and then doxorubicin was loaded onto PEGylated iron oxide nanoparticles. FT-IR was used to ensure PEG binding to nanoparticles and loading the drug onto nanoshell. Comparison of the mean size and the crystalline structure of nanoparticles were performed by TEM and X-ray diffraction pattern. Then, the effect of cytotoxicity was evaluated on AGS and MCF-7 cancer cells by MTT assay.

According to FT-IR results, the presence of O-H and C-H bands at 2927 cm^-1 and 3392 cm^-1 peaks correlated with PEG binding to nanoparticles. XRD pattern showed the cubic spinel structure of trapped magnetite nanoparticles carrying medium with a mean size of 14 nm. 21.67% of Doxorubicin was loaded into Fe₃O₄-PEG nanoparticles, which the highest drug release recorded during the first 24 hours. MTT assay at 24, 48 and 72 h treatments showed that with increasing concentrations of doxorubicin loaded Fe₃O₄-PEG nanoparticles from 0 to 50 μm, the cytotoxic effects of the drug gradually increase.

This study showed that PEGylation of iron oxide nanoparticles and using them in drug delivery process to increase the effect of Doxorubicin on AGS and MCF-7 cancer cells

Keywords

Polyethylene glycol

Doxorubicin

Iron oxide nanoparticles

AGS and MCF-7 cancer cells

20.1001.1.23222115.1399.11.2.6.7

Subjects

Nanotechnology

1]. Alireza S, Mehdi N, Ali M, Alireza M, Reza M, Parkin. Cancer occurrence in Iran in 2002, an international perspective. Asian Pacific journal of cancer prevention.2005; 6 (3), 359
[2]. Moore KL, Dalley AF, Agur AM.(2013). Clinically oriented anatomy: Lippincott Williams & Wilkins; PP 270-300.
[3]. Wiechmann L, Kuerer HMJC. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008;112(10):2130-42.
[4]. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
[5]. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971-9.
[6]. Haghiralsadat F, Amoabediny G, Sheikhha MH, Zandieh‐doulabi B, Naderinezhad S, Helder MN, et al. New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity. Chemical Biology and Drug Design. 2017;90(3):368-79.
[7]. Ariga K, Lvov YM, Kawakami K, Ji Q, Hill J. Layer-by-layer self-assembled shells for drug delivery. Adv Drug Deliv Rev. 2011;63(9):762-71.
[8]. Kim J-E, Shin J-Y, Cho M-H. Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects. Arch Toxicol. 2012;86(5):685-700.
[9]. Bakhtiary Z, Saei AA, Hajipour MJ, Raoufi M, Vermesh O, Mahmoudi M .Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges. Nanomedicine. 2016;12(2):287-307.
[10]. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
[11]. Veiseh O, Gunn JW, Zhang MJ. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304.
[12]. Gautier J, Allard-Vannier E, Munnier E, Soucé M, Chourpa I. Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. J Control Release. 2013;169(1-2):48-61.
[13]. Munnier E, Cohen-Jonathan S, Hervé K, Linassier C, Soucé M, Dubois P, et al. Doxorubicin delivered to MCF-7 cancer cells by superparamagnetic iron oxide nanoparticles: effects on subcellular distribution and cytotoxicity. 2011;13(3):959-71.
[14]. Babaei E, Sadeghizadeh M, Hassan ZM, Feizi MAH, Najafi F, Hashemi I. Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol. 2012;12(1):226-34.
[15]. Azar NTP, Mutlu P, Khodadust R, Gunduz UJJBC. Poly (amidoamine)(PAMAM) nanoparticles: synthesis and biomedical applications. J. Biol. & Chem., 2013;41(3):289-99.
[16]. Unsoy G, Gunduz U. Targeted drug delivery via chitosan-coated magnetic nanoparticles. Nanostructures for Drug Delivery. 2017. p. 835-64.
[17]. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 2005;10(21):1451-8.
[18]. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono KJIjop. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm. 2010;383(1-2):293-6.
[19]. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WMJM. Poly (ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. AAPS J. 2009;35(9):3456-62.
[20]. Sun J, et al. Synthesis and characterization of biocompatible Fe3O4 nanoparticles. Journal of Biomedical Materials.2007;333-341.
[21]. Iida H, Takayanagi K, Nakanishi T, Osaka T. Synthesis of Fe3O4 nanoparticles with various sizes and magnetic properties by controlled hydrolysis. Journal of Colloid and InterfaceScience.2007;274-280.
[22]. Gupta AK, Wells SJIton. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans Nanobioscience. 2004;3(1):66-73.
[23]. Anbarasu M, Anandan M, Chinnasamy E, Gopinath V, Balamurugan KJSAPAM, Spectroscopy B. Synthesis and characterization of polyethylene glycol (PEG) coated Fe3O4 nanoparticles by chemical co-precipitation method for biomedical applications. Spectrochim Acta A Mol Biomol Spectrosc. 2015;135:536-9.
[24]. Wen-wen C, Si-jia H, Chen-xi W, Qiang Z, Chuan-lu H, Juan D, et al., editors. Cytotoxicity effects of nano-Fe3O4 on HeLa cells. J Clin Pharmacol. 2009;49(8):947-56
[25]. Jeng HA, Swanson J, A HP. Toxicity of metal oxide nanoparticles in mammalian cells. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(12):2699-711.
[26]. Aljarrah K, Mhaidat NM, Al-Akhras M-AH, Aldaher AN, Albiss B, Aledealat K, et al. Magnetic nanoparticles sensitize MCF-7 breast cancer cells to doxorubicin-induced apoptosis. World J Surg Oncol. 2012;10(1):62.
[27]. Schweiger C, Pietzonka C, Heverhagen J, Kissel T. Novel magnetic iron oxide nanoparticles coated with poly (ethylene imine)-g-poly (ethylene glycol) for potential biomedical application: synthesis, stability, cytotoxicity and MR imaging. International Journal of Pharmaceutics . 2011;408(1-2):130-7.
[28]. Naqvi S, Samim M, Abdin M, Ahmed FJ, Maitra A, Prashant C, et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine. 2010;5:983.
[29]. Ayen WY, Garkhal K, Kumar N (2011) Doxorubicin-loaded (PEG) 3-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. Molecular pharmaceutics 8:466-478
[30]. Lazhen Shen, Bei Li and Yongsheng Qiao. Fe3O4 Nanoparticles in targeted Drug/Gene delivery systems. Materials 2018, 11(2), 324